KI
NBIX icon

Kapitalo Investimentos’s Neurocrine Biosciences NBIX Stock Holding History

Kapitalo Investimentos’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-503
Closed -$66.3K – 459
2023
Q4 		$66.3K Buy
+503
New +$57.9K 0.01% 437
2023
Q3 		– Sell
-472
Closed -$44.5K – 646
2023
Q2 		$44.5K Sell
472
-709
-60% -$69.3K 0.01% 408
2023
Q1 		$120K Buy
+1,181
New +$123K 0.04% 285

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Kapitalo Investimentos's NBIX Position: Q1 2024 in Review

Kapitalo Investimentos sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 503 shares — an estimated $66.3K sold.

Kapitalo Investimentos first reported a position in NBIX in Q1 2023 and held it in 3 quarters. The position peaked at $120K in Q1 2023. 590 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Kapitalo Investimentos reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Kapitalo Investimentos sold 503 Neurocrine Biosciences shares in Q1 2024, an estimated $66.3K.
  • Kapitalo Investimentos first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 3 quarters.
  • Kapitalo Investimentos's Neurocrine Biosciences position peaked at $120K in Q1 2023.
  • 590 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Kapitalo Investimentos's 13F filing for Q1 2024, filed 15 May 2024.